Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Paul Bebbington and Elizabeth Kuipers, two academics whose lives are now impacted by Paul’s diagnosis of Alzheimer’s, offer brave accounts of the day-to-day experiences of living with dementia and being a care provider in an initiative to reduce stigma.
The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
ADI members in the Middle East region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
ADI members in the African region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
The World Alzheimer Report 2020 has been awarded the European Healthcare Design (EHD) 2021 Award for Outstanding Contribution to Global Knowledge.
Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.